Expert insights into a 67-year-old man's journey through relapsed/refractory diffuse large B-cell lymphoma, exploring diagnosis, treatment options, and outcomes.
Stay up to date on practice-changing data in community practice.
Study Indicates Early Resolution of CRS, Neurological Events After Axi-Cel
Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ciloleucel in large B-cell lymphoma.
Read More
Improving Quality of Life in LR-MDS Through Anemia Treatment
During a live event, Chris Benton, MD, discussed the focus on anemia management, reducing transfusions, and improving quality of life in MDS.
SGX301 Shows Rapid and Durable Responses in Early-Stage CTCL
SGX301 has shown rapid and sustained benefit in early cutaneous T-cell lymphoma in an investigator-initiated study, with good safety.
AFM13/NK Cell Combination Shows Encouraging Responses in R/R Lymphoma
AFM13-NK combo shows high response rates in relapsed/refractory lymphoma trial, per survival data reported at 20 months.
FDA OKs Phase 3 Study of Linperlisib in Peripheral T-Cell Lymphoma
Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.
Optimizing Tagraxofusp in BPDCN with Early CPS Detection Strategies
Marlise R. Luskin, MD, MSCE, discusses the vigilant monitoring required for capillary leak syndrome with tagraxofusp in BPDCN.